Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAFERGOT vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Acute treatment of migraine headaches with or without aura,Acute treatment of cluster headache episodes
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
2.5-3.9 hours (ergotamine); clinical context: t1/2 may be prolonged in hepatic impairment.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Primarily hepatic via CYP3A4; ergotamine is extensively metabolized, and caffeine is metabolized via CYP1A2.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Primarily hepatic metabolism and biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for most of the administered dose.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
98-99% bound to plasma proteins, primarily albumin.
Negligible for electrolytes and dextrose (<5%).
1.1-2.0 L/kg; clinical meaning: extensive tissue distribution, particularly into liver and spleen.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Oral: <5% due to extensive first-pass metabolism; Sublingual: approximately 15-20%; Rectal: approximately 20-30%.
Intravenous: 100%.
Contraindicated in severe renal impairment. In moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): use with caution; dose reduction not specifically defined but monitor for adverse effects. Mild impairment (e GFR ≥60 m L/min/1.73 m²): no adjustment needed.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
Contraindicated in Child-Pugh Class C. Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50% and monitor. No specific dose recommendations from manufacturer; clinical judgment advised.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Not recommended for use in pediatric patients due to risk of ergotism and lack of safety data. No established weight-based dosing.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to increased risk of ergotism, renal/hepatic impairment, and drug interactions. Lower initial dose (e.g., 1 tablet) and careful monitoring. Avoid in patients over 65 with significant vascular disease.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
Serious and/or life-threatening peripheral ischemia has been associated with coadministration of ergotamine with potent CYP3A4 inhibitors (including protease inhibitors, macrolide antibiotics, and azole antifungals).
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of ergotism (ischemia, gangrene) with prolonged use or overdosage,May cause vasospastic reactions, including coronary artery vasospasm and myocardial infarction,Rebound headache (medication overuse headache) with frequent use,Caffeine withdrawal may exacerbate headaches,Avoid concurrent use with potent CYP3A4 inhibitors
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Peripheral vascular disease,Coronary artery disease,Hypertension (uncontrolled),Sepsis,Severe hepatic or renal impairment,Pregnancy (Category X),Breastfeeding,Concurrent use of potent CYP3A4 inhibitors
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as Cafergot contains caffeine and may cause additive stimulation or toxicity. Limit caffeine to no more than 200 mg per day during treatment.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (including micrognathia, microphthalmia, cleft palate, and limb defects). Second and third trimesters: continued risk of uteroplacental insufficiency, intrauterine growth restriction, preterm labor, and fetal distress due to vasoconstriction and increased uterine tone.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Contraindicated during breastfeeding. Ergotamine reduces prolactin secretion and may suppress lactation. It is excreted into breast milk; M/P ratio not established. Reported infant adverse effects include vomiting, diarrhea, and seizures. Risk of vasospasm and ergotism in the infant.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Contraindicated in pregnancy; no dosing adjustments recommended. Use is not safe; alternative therapy should be sought.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Cafergot is ergotamine-caffeine combination for acute migraine. Avoid in pregnancy, uncontrolled hypertension, CAD, and peripheral vascular disease. Maximum dose: 6 tablets per attack or 10 tablets per week. Use at first sign of migraine. Not for prophylaxis. Can cause ergotism with prolonged use. Monitor for signs of ischemia.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
Take at the first sign of migraine headache for best effect.,Do not take more than 6 tablets per attack or 10 tablets per week.,Avoid use if you are pregnant, breastfeeding, or have high blood pressure, heart disease, or circulation problems.,Seek emergency care if you experience severe stomach pain, chest pain, numbness, tingling, or muscle cramps.,Do not take with other ergotamine drugs or strong CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics).,Store at room temperature, away from heat and moisture.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAFERGOT vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
CAFERGOT is a Antimigraine Agent (Ergot Alkaloid) that works by Ergotamine is a serotonin (5-HT1B/1D) receptor agonist that causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation. Caffeine is a methylxanthine that enhances ergotamine absorption and may contribute to vasoconstriction.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAFERGOT and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAFERGOT is: 1 to 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack or 10 tablets per week. Alternatively, 1 rectal suppository (ergotamine tartrate 2 mg and caffeine 100 mg) at onset, repeat once after 1 hour if needed, maximum 2 suppositories per attack or 5 per week.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAFERGOT and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAFERGOT is classified as Category C. FDA Category X. First trimester: ergotamine is a potent vasoconstrictor and uterine stimulant, associated with increased risk of spontaneous abortion, congenital anomalies (includi. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.